查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016266

家禽疫苗市場：2026-2032年全球市場預測（按產品類型、物種、給藥途徑、最終用戶和分銷管道分類）

Poultry Vaccine Market by Product Type, Species, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，家禽疫苗市場價值將達到 28.5 億美元，到 2026 年將成長到 30 億美元，到 2032 年將達到 43.7 億美元，複合年成長率為 6.26%。

主要市場統計數據
基準年 2025 28.5億美元
預計年份：2026年 30億美元
預測年份：2032年 43.7億美元
複合年成長率 (%) 6.26%

對不斷發展的家禽疫苗生態系統進行了簡潔且權威的概述，將科學創新、生產需求和商業性重點聯繫起來。

受科學創新、生產模式轉變以及生物安全期望不斷提高的驅動，家禽疫苗領域正在迅速發展。本執行摘要整合了影響全球家禽系統疫苗研發和部署的關鍵主題，為產業領導者提供了一個連結科學、政策和商業的全面觀點。本概要重點在於技術進步、監管變化、供應鏈趨勢和終端用戶行為，所有這些因素共同決定了疫苗研發者、經銷商和家禽生產商決策的優先事項。

科學、監管和營運創新的融合如何加速家禽系統平台多樣化和綜合疫苗接種策略？

現代家禽疫苗接種格局正受到多種變革力量的共同影響而重塑，這些力量在加速創新的同時，也暴露出系統性脆弱性。首先，平台多樣化正在加速發展，重組技術和核酸技術正從實驗階段走向商業性實用化。與傳統的減毒或去活化疫苗相比，這種轉變能夠產生更具針對性的免疫反應，縮短研發週期，並改變疫苗研發管線和研發人員的投資策略。

關稅引發的貿易摩擦如何推動了疫苗價值鏈全過程的供應鏈重組、區域生產策略調整和物流最佳化？

美國近期加徵的關稅累積效應，為疫苗生產商、供應商和分銷網路帶來了一系列複雜的挑戰和戰略轉折點。關稅提高了依賴進口的生產商取得某些原料和成品的成本，促使其進行供應鏈重組並增強採購韌性。為此，許多相關人員正在加快供應商認證流程，並發展符合品質和監管要求的區域供應商，以降低關稅波動帶來的風險。

一個多維細分框架，明確了目標策略中使用的產品平台的選擇、管理方法、每種類型的需求以及分銷管道。

細分市場層面的差異化對於了解整個家禽疫苗市場的採用趨勢和投資重點至關重要。從產品類型來看，去活化疫苗和減毒活病毒疫苗等傳統平台在安全性和有效性已得到驗證的細分市場中仍然發揮著重要作用，而重組疫苗因其模組化和適應性而備受關注。在重組疫苗領域，mRNA平台、蛋白質次單元構建體和病毒載體系統分別代表不同的研發管道和生產​​結構。即使在病毒載體內部，腺病毒、甲病毒和痘病毒骨架之間也存在技術差異，每種骨架都具有獨特的免疫抗原性和生產特性，這會影響研發人員的選擇和最終用戶的適用性。

生產規模、監管方式和物流現實的區域差異如何影響全球疫苗的選擇和部署策略？

區域趨勢對整個家禽生產系統的疫苗研發重點、採購行為、監管方法和分銷體係都具有決定性影響。美洲地區擁有成熟的商業家禽產業，其特點是生物安全規程高度整合、自動化給藥技術廣泛應用以及對生產力指標的高度重視。在此背景下，商業生產者積極投資於高效平台，以實現規模經濟、獲得監管認可，並在生產力和禽群健康方面取得可預測的成果，從而推動創新。

競爭定位和夥伴關係策略揭示了競爭製造商和生物技術創新者如何塑造疫苗供應和附加價值服務。

家禽疫苗產業的競爭動態呈現出傳統生技藥品專家、生物技術創新者和靈活敏捷的區域性開發商並存的態勢，各方都憑藉其平台專長、分銷網路和監管記錄佔據著各自的戰略地位。成熟的疫苗生產商在規模化生產、檢驗的低溫運輸物流和龐大的安全資料庫方面保持優勢，這些優勢有助於獲得監管部門的核准，並讓商業客戶安心。同時，專注於重組和核酸平台的新興生物技術參與企業正在重塑創新前沿，它們展現出快速的候選疫苗最佳化、平台模組化和跨病原體適應性。

採取具體且優先的企業措施，以加速平台適應性，增強供應鏈韌性，並擴大在各種生產系統中的商業性應用。

產業領導企業可以採取多項切實可行的措施來增強自身韌性，加速創新成果的實用化，並擴大其在禽類市場的商業性影響力。首先，在開發平臺中優先考慮平台無關功能，以實現快速抗原交換和跨病原體反應。模組化平台能夠在不影響監管合規性的前提下，降低應對新發感染疾病徵兆所需的時間和成本。其次，投資最佳化給藥系統，例如氣霧劑、噴霧劑和口服給藥系統，以降低給藥成本，並促進這些系統在面臨嚴重勞動力短缺的高密度生產系統中得到應用。

為了得出策略性結論，我們採用了高度透明、以證據為基礎的調查方法，結合了專家訪談、文獻檢驗和情境壓力測試。

本執行摘要的研究是基於結構化、多維度的調查方法，旨在產生可重複的洞見，並揭示對相關人員的實際意義。主要資訊來源包括對疫苗研發、獸醫學和家禽生產領域專家的深入訪談，以及與重組和核酸平台開發人員的技術簡報。二級資訊來源包括同儕審查的科學文獻、監管指導文件、產業白皮書和供應鏈物流分析，從而能夠對趨勢進行三角檢驗，並檢驗營運限制因素。

綜合策略結論強調，在技術、商業和供應方面採取統一的韌性方法，對於最大限度地提高疫苗的有效性至關重要。

當前家禽疫苗接種的發展趨勢為能夠將技術創新與切實可行的分銷和生產策略相結合的相關人員提供了明確的機會。重組疫苗平台和先進的給藥方法不再是邊緣因素，而是成為生產者和監管機構在疾病預防和生產連續性方面考慮的核心要素。同時，貿易政策的變化和物流限制凸顯了建立具有韌性的供應鏈和靈活的商業化模式的必要性，以應對快速的市場波動和長期的結構性變化。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 家禽疫苗市場：依產品類型分類

  • DNA
  • 失活
  • 減毒活病毒疫苗
  • 重組
    • mRNA
    • 蛋白質次單元
    • 病毒載體
      • 腺病毒
      • 甲病毒
      • 痘病毒
  • 次單元

第9章 家禽疫苗市場：依類型分類

  • 雞
  • 鴨子
  • 火雞

第10章：家禽疫苗市場：依給藥途徑分類

  • 注射藥物
    • 肌肉內部
    • 皮下
  • 口服
  • 噴
    • 氣霧劑
    • 噴

第11章 家禽疫苗市場：依最終用戶分類

  • 家庭養雞場
  • 商業農場
    • 肉雞養殖場
    • 蛋雞養殖場
  • 研究機構

第12章 家禽疫苗市場：依通路分類

  • 線上管道
    • EC市場
    • 製造商網站
  • 動物醫院
    • 公立醫院
    • 私立醫院
  • 獸藥
    • 連鎖藥局
    • 獨立經營藥房

第13章 家禽疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 家禽疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 家禽疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國家禽疫苗市場

第17章：中國家禽疫苗市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AniCon Labor GmbH
  • Boehringer Ingelheim Animal Health GmbH
  • Ceva Sante Animale SA
  • Elanco Animal Health Incorporated
  • HIPRA, SAU
  • Indian Immunologicals Limited
  • Merck & Co., Inc.
  • Phibro Animal Health Corporation
  • Vaxxinova Group BV
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-0375F3EA9C41

The Poultry Vaccine Market was valued at USD 2.85 billion in 2025 and is projected to grow to USD 3.00 billion in 2026, with a CAGR of 6.26%, reaching USD 4.37 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.85 billion
Estimated Year [2026] USD 3.00 billion
Forecast Year [2032] USD 4.37 billion
CAGR (%) 6.26%

A concise and authoritative synthesis of the evolving poultry vaccine ecosystem connecting scientific innovation, production imperatives, and commercial priorities

The poultry vaccine landscape is undergoing rapid evolution driven by scientific innovation, changing production models, and heightened biosecurity expectations. This executive summary synthesizes critical themes shaping vaccine development and deployment across global poultry systems, offering leaders a consolidated perspective that bridges science, policy, and commerce. The narrative focuses on technological trajectories, regulatory inflections, supply chain dynamics, and end-user behavior that together define decision-making priorities for vaccine developers, distributors, and poultry producers.

In recent years, advancements in recombinant technologies and precision delivery mechanisms have begun to redefine the risk-benefit calculus for vaccination programs. Concurrently, producers face increasing pressure to adopt solutions that balance efficacy, cost efficiency, and operational compatibility with intensive production systems. As a result, research and commercial efforts are shifting toward platforms that can be scaled, adapted to shifting pathogen landscapes, and integrated with digital health monitoring systems. The introduction frames subsequent sections by outlining how transformative shifts, trade dynamics, segmentation nuances, regional patterns, competitive positioning, and recommended actions intersect to inform robust strategic planning for stakeholders across the poultry vaccine value chain.

How converging scientific, regulatory, and operational innovations are accelerating platform diversification and integrated vaccination strategies across poultry systems

The contemporary landscape of poultry vaccination is being reshaped by several convergent transformative forces that accelerate innovation while exposing systemic vulnerabilities. First, platform diversification has gained momentum, with recombinant approaches and nucleic acid technologies moving from experimental stages toward commercial viability. This shift is enabling more targeted immune responses and shorter development cycles relative to classical attenuated or inactivated approaches, altering vaccine pipelines and developer investment strategies.

Second, delivery innovations are changing adoption dynamics on farms. Non-invasive routes such as aerosolized sprays and optimized oral formulations are improving ease of administration for large flocks and reducing labor burdens, which in turn is producing stronger demand from commercial producers seeking operational efficiencies. Third, regulatory landscapes are progressively evolving to accommodate novel biologics, prompting more harmonized frameworks in some jurisdictions while creating intermittent uncertainty in others. This regulatory heterogeneity incentivizes developers to design platforms with cross-border adaptability.

Fourth, digital tools and diagnostics are increasingly linked to vaccination strategies, enabling real-time monitoring of immune response and outbreak signals, and thereby making vaccination decisions more data-driven. Finally, heightened emphasis on animal welfare and antimicrobial stewardship is pushing vaccines to the forefront as both preventive health tools and alternatives to therapeutic antibiotic use. Collectively, these shifts indicate a transition toward smarter, more integrated vaccination ecosystems in poultry production.

How tariff-driven trade frictions have catalyzed supply chain reconfiguration, regional production strategies, and logistics optimization across the vaccine value chain

The cumulative impact of recent tariff actions originating from the United States has introduced a complex set of headwinds and strategic inflection points for vaccine producers, suppliers, and distribution networks. Tariff measures have increased the landed cost of selected inputs and finished goods for import-dependent manufacturers, prompting supply chain reconfiguration and an increased emphasis on sourcing resilience. In response, many stakeholders have accelerated supplier qualification processes and explored regional suppliers with compatible quality and regulatory credentials to mitigate exposure to tariff volatility.

Moreover, tariff-driven cost pressures have amplified the importance of cold-chain optimization and inventory management. Organizations with robust logistics capabilities have been able to absorb short-term cost shocks by streamlining transport consolidation, renegotiating freight terms, and leveraging longer lead times to smooth procurement cycles. Conversely, smaller manufacturers and independent distributors have experienced margin compression, which in turn has encouraged strategic partnerships, co-manufacturing arrangements, and selective vertical integration to preserve access and continuity of supply.

Trade policy adjustments have also accelerated conversations about nearshoring and regional manufacturing hubs as long-term solutions to tariff risk. Investors and executives are increasingly evaluating the trade-offs between capital expenditure for localized capacity and the ongoing softening of cross-border trade flows. In parallel, regulatory compliance and quality assurance remain pivotal as jurisdictions adapt their import-review processes, underscoring the need for transparent documentation and harmonized standards to sustain cross-border vaccine availability despite tariff-related disruptions.

A multidimensional segmentation framework that clarifies product platform choice, delivery modalities, species-specific needs, and distribution pathways for targeted strategies

Segment-level differentiation is central to understanding adoption dynamics and investment priorities across the poultry vaccine landscape. Product type segmentation reveals that traditional platforms such as inactivated and live attenuated vaccines continue to play key roles where established safety and efficacy profiles exist, while recombinant categories are attracting substantial attention for their modularity and adaptability. Within recombinant approaches, mRNA platforms, protein subunit constructs, and viral vector systems demonstrate distinct development pathways and manufacturing footprints. Viral vectors themselves show further technical differentiation across adenovirus, alphavirus, and poxvirus backbones, each bringing specific immunogenic and production characteristics that influence developer choice and end-user suitability.

Species segmentation-spanning chickens, ducks, and turkeys-affects antigen selection, delivery methods, and vaccination schedules because each species presents unique husbandry practices and disease exposure patterns. Route of administration is another critical axis: injectable formats, delivered intramuscularly or subcutaneously, remain prevalent where precise dosing and systemic immunity are priorities, while oral and spray routes, including aerosol and fogging spray modalities, offer practical advantages for mass administration and labor-constrained operations. End-user segmentation distinguishes backyard operations, commercial farms, and research institutions, with commercial broiler and layer farms requiring scalable, cost-effective solutions that integrate into high-throughput production systems, whereas backyard settings prioritize ease of use and minimal cold-chain dependency. Distribution channel segmentation complements these distinctions by shaping access and service models; online channels through e-commerce marketplaces and manufacturer websites offer broader reach and convenience, veterinary hospitals-both government and private-provide clinical oversight and product stewardship, and veterinary pharmacies, whether chain or independent, facilitate localized access and point-of-care advice. These interacting segmentation dimensions create a multidimensional framework for prioritizing R&D investments, tailoring commercialization strategies, and designing distribution partnerships that align with end-user needs and operational realities.

How diverse regional production intensities, regulatory approaches, and logistical realities shape vaccine preferences and deployment strategies globally

Regional dynamics exert a defining influence on vaccine development priorities, procurement behavior, regulatory approaches, and distribution architectures across poultry production systems. The Americas region is characterized by a mature commercial poultry industry with advanced integration of biosecurity protocols, broad use of automated administration technologies, and a strong emphasis on productivity metrics. In this context, innovation is driven by scale efficiencies, regulatory reliability, and commercial producers' willingness to invest in high-efficacy platforms that deliver predictable returns in performance and flock health.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization varies and resource availability ranges widely. In several European markets, stringent regulatory frameworks and strong animal welfare norms favor licensed, well-characterized vaccines and comprehensive surveillance programs. In parts of the Middle East and Africa, vaccination strategies must reconcile logistical constraints, fragmented cold chains, and diverse production systems, which increases demand for thermostable formulations and simplified delivery options.

Asia-Pacific hosts some of the fastest-evolving production systems and high-density poultry populations, driving intensive focus on scalable delivery mechanisms, rapid-response platforms, and regionally tailored antigen panels to address endemic and emerging threats. Cross-border trade, dense production clusters, and strong governmental investment in disease control amplify the urgency for adaptable vaccine solutions that can be deployed at scale while aligning with local regulatory and manufacturing capacities. Across all regions, regional policy shifts, zoonotic risk awareness, and localized production imperatives influence procurement timelines and product performance expectations.

Competitive positioning and partnership strategies that reveal how legacy manufacturers and biotech innovators are shaping vaccine availability and value-added services

Competitive dynamics in the poultry vaccine sector reflect a mix of legacy biologics specialists, biotech innovators, and nimble regional developers, each occupying strategic positions based on platform expertise, distribution reach, and regulatory track record. Established vaccine manufacturers retain advantages in large-scale production, validated cold-chain logistics, and extensive safety databases that ease regulatory approvals and reassure commercial customers. At the same time, biotech entrants focusing on recombinant and nucleic acid platforms are reshaping the innovation frontier by demonstrating faster candidate iteration, platform modularity, and potential for cross-pathogen adaptability.

Partnership models are increasingly prominent; collaborations between research institutions and commercial entities accelerate translational pathways, while co-manufacturing and licensing agreements expand production capacity and geographic reach. Distribution strategies vary from direct-to-producer engagement in highly integrated markets to channel partnerships with veterinary hospitals and pharmacies in markets where clinical oversight is crucial. Strategic differentiators include proprietary adjuvant technologies, thermostability innovations, and validated delivery systems that reduce administration complexity. In addition, companies investing in data integration-linking vaccination events with flock health records and diagnostic outcomes-are positioned to offer value-added services that deepen customer relationships and create sticky revenue streams through service subscriptions and analytics.

Concrete and prioritized measures for companies to accelerate platform adaptability, strengthen supply resilience, and expand commercial adoption across diverse production systems

Industry leaders can adopt several actionable steps to strengthen resilience, accelerate innovation translation, and expand commercial impact across poultry markets. First, prioritize platform-agnostic capabilities in development pipelines to enable faster antigen swaps and cross-pathogen responsiveness; modular platforms reduce time and cost to adapt to emergent disease signals without compromising regulatory compliance. Second, invest in delivery system optimization, including aerosol, fogging, and oral modalities, to lower administration costs and increase adoption in high-density production systems where labor constraints are acute.

Third, reinforce supply chain resilience by diversifying input sources, qualifying regional contract manufacturers, and expanding thermostable product lines to reduce cold-chain dependence. Fourth, pursue strategic partnerships that combine technical innovation with distribution strength, such as licensing arrangements, co-manufacturing, and data-sharing agreements with diagnostic providers to create closed-loop health solutions. Fifth, engage proactively with regulators and industry bodies to support harmonized dossiers and to pilot adaptive approval pathways for platform technologies. Finally, align commercial models with end-user realities by offering bundled services-training, monitoring, and outcome analytics-that translate product efficacy into operational value and make vaccination investments easier to justify for producers with differing scales and capacities. Implementing these measures will improve speed-to-market, adoption rates, and long-term sustainability across varied production landscapes.

A transparent evidence-based methodology combining expert interviews, literature triangulation, and scenario stress tests to inform strategic conclusions

The research underpinning this executive summary relies on a structured, multi-source methodology designed to produce replicable insights and to surface practical implications for stakeholders. Primary inputs included in-depth interviews with subject-matter experts across vaccine R&D, veterinary practice, and poultry production, supplemented by technical briefings with developers of recombinant and nucleic acid platforms. Secondary sources encompassed peer-reviewed scientific literature, regulatory guidance documents, industry whitepapers, and supply chain logistics analyses to triangulate trends and validate operational constraints.

Analytical methods combined qualitative synthesis with scenario-based stress testing to explore the ramifications of trade and regulatory shifts on supply continuity and product deployment. The approach emphasized cross-validation of claims through multiple evidence streams to reduce bias and to ensure findings reflect operational realities rather than aspirational projections. Limitations are acknowledged where data gaps exist, particularly around proprietary clinical performance metrics and confidential commercial arrangements. To mitigate this, the methodology prioritized transparency in assumptions, documented data provenance, and recommended targeted follow-up engagements to drill deeper into areas requiring quantitative verification or bespoke local intelligence.

Synthesis of strategic conclusions emphasizing the imperative for integrated technological, commercial, and supply resilience actions to realize vaccine impact

The current trajectory of poultry vaccination signals a clear opportunity for stakeholders who can integrate technological innovation with pragmatic distribution and production strategies. Recombinant platforms and advanced delivery methods are no longer peripheral; they are becoming central to how producers and regulators think about disease prevention and production continuity. At the same time, trade policy shifts and logistical constraints underscore the need for resilient supply architectures and agile commercialization models that can adapt to both acute disruptions and longer-term structural changes.

Decision-makers should therefore balance investments across near-term operational gains-such as thermostability and simplified administration-and longer-term platform development that enables rapid response to emerging pathogens. Cross-sector collaboration, including public-private partnerships and alliances with diagnostic and digital health providers, will be instrumental in converting vaccine efficacy into measurable flock health outcomes. By aligning R&D priorities, regulatory engagement, and distribution strategies, stakeholders can accelerate the transition from proof-of-concept innovations to widely adopted, field-ready solutions that enhance biosecurity and producer profitability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Poultry Vaccine Market, by Product Type

  • 8.1. DNA
  • 8.2. Inactivated
  • 8.3. Live Attenuated
  • 8.4. Recombinant
    • 8.4.1. mRNA
    • 8.4.2. Protein Subunit
    • 8.4.3. Viral Vector
      • 8.4.3.1. Adenovirus
      • 8.4.3.2. Alphavirus
      • 8.4.3.3. Poxvirus
  • 8.5. Subunit

9. Poultry Vaccine Market, by Species

  • 9.1. Chicken
  • 9.2. Duck
  • 9.3. Turkey

10. Poultry Vaccine Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Intramuscular
    • 10.1.2. Subcutaneous
  • 10.2. Oral
  • 10.3. Spray
    • 10.3.1. Aerosol
    • 10.3.2. Fogging

11. Poultry Vaccine Market, by End User

  • 11.1. Backyard Farms
  • 11.2. Commercial Farms
    • 11.2.1. Broiler Farms
    • 11.2.2. Layer Farms
  • 11.3. Research Institutes

12. Poultry Vaccine Market, by Distribution Channel

  • 12.1. Online Channels
    • 12.1.1. E Commerce Marketplaces
    • 12.1.2. Manufacturer Websites
  • 12.2. Veterinary Hospitals
    • 12.2.1. Government Hospitals
    • 12.2.2. Private Hospitals
  • 12.3. Veterinary Pharmacies
    • 12.3.1. Chain Pharmacies
    • 12.3.2. Independent Pharmacies

13. Poultry Vaccine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Poultry Vaccine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Poultry Vaccine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Poultry Vaccine Market

17. China Poultry Vaccine Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AniCon Labor GmbH
  • 18.6. Boehringer Ingelheim Animal Health GmbH
  • 18.7. Ceva Sante Animale S.A.
  • 18.8. Elanco Animal Health Incorporated
  • 18.9. HIPRA, S.A.U.
  • 18.10. Indian Immunologicals Limited
  • 18.11. Merck & Co., Inc.
  • 18.12. Phibro Animal Health Corporation
  • 18.13. Vaxxinova Group B.V.
  • 18.14. Virbac S.A.
  • 18.15. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL POULTRY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POULTRY VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POULTRY VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPECIES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POULTRY VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POULTRY VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POULTRY VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES POULTRY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA POULTRY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POULTRY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POULTRY VACCINE MARKET SIZE, BY DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POULTRY VACCINE MARKET SIZE, BY DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POULTRY VACCINE MARKET SIZE, BY DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POULTRY VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POULTRY VACCINE MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POULTRY VACCINE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POULTRY VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POULTRY VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POULTRY VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POULTRY VACCINE MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POULTRY VACCINE MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POULTRY VACCINE MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POULTRY VACCINE MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POULTRY VACCINE MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POULTRY VACCINE MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POULTRY VACCINE MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POULTRY VACCINE MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POULTRY VACCINE MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POULTRY VACCINE MARKET SIZE, BY ALPHAVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POULTRY VACCINE MARKET SIZE, BY ALPHAVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POULTRY VACCINE MARKET SIZE, BY ALPHAVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POULTRY VACCINE MARKET SIZE, BY POXVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POULTRY VACCINE MARKET SIZE, BY POXVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POULTRY VACCINE MARKET SIZE, BY POXVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHICKEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHICKEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHICKEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POULTRY VACCINE MARKET SIZE, BY DUCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POULTRY VACCINE MARKET SIZE, BY DUCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POULTRY VACCINE MARKET SIZE, BY DUCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POULTRY VACCINE MARKET SIZE, BY TURKEY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POULTRY VACCINE MARKET SIZE, BY TURKEY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POULTRY VACCINE MARKET SIZE, BY TURKEY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POULTRY VACCINE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POULTRY VACCINE MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POULTRY VACCINE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POULTRY VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POULTRY VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POULTRY VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL POULTRY VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POULTRY VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POULTRY VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL POULTRY VACCINE MARKET SIZE, BY AEROSOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL POULTRY VACCINE MARKET SIZE, BY AEROSOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL POULTRY VACCINE MARKET SIZE, BY AEROSOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL POULTRY VACCINE MARKET SIZE, BY FOGGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL POULTRY VACCINE MARKET SIZE, BY FOGGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POULTRY VACCINE MARKET SIZE, BY FOGGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL POULTRY VACCINE MARKET SIZE, BY BACKYARD FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL POULTRY VACCINE MARKET SIZE, BY BACKYARD FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL POULTRY VACCINE MARKET SIZE, BY BACKYARD FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL POULTRY VACCINE MARKET SIZE, BY BROILER FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL POULTRY VACCINE MARKET SIZE, BY BROILER FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL POULTRY VACCINE MARKET SIZE, BY BROILER FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL POULTRY VACCINE MARKET SIZE, BY LAYER FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL POULTRY VACCINE MARKET SIZE, BY LAYER FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL POULTRY VACCINE MARKET SIZE, BY LAYER FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL POULTRY VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL POULTRY VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL POULTRY VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL POULTRY VACCINE MARKET SIZE, BY E COMMERCE MARKETPLACES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL POULTRY VACCINE MARKET SIZE, BY E COMMERCE MARKETPLACES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL POULTRY VACCINE MARKET SIZE, BY E COMMERCE MARKETPLACES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL POULTRY VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL POULTRY VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL POULTRY VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL POULTRY VACCINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL POULTRY VACCINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL POULTRY VACCINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL POULTRY VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL POULTRY VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL POULTRY VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL POULTRY VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL POULTRY VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL POULTRY VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL POULTRY VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS POULTRY VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL POULTRY VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 248. GCC POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. GCC POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. GCC POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 251. GCC POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 252. GCC POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 253. GCC POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. GCC POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 255. GCC POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 256. GCC POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. GCC POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 258. GCC POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. GCC POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 260. GCC POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 261. GCC POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 290. G7 POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. G7 POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. G7 POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 293. G7 POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 294. G7 POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 295. G7 POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 296. G7 POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 297. G7 POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 298. G7 POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. G7 POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 300. G7 POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 301. G7 POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 302. G7 POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 303. G7 POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 304. NATO POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 305. NATO POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. NATO POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 307. NATO POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 308. NATO POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 309. NATO POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 310. NATO POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 311. NATO POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 312. NATO POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. NATO POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 314. NATO POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 315. NATO POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 316. NATO POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 317. NATO POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 318. GLOBAL POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES POULTRY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED STATES POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA POULTRY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 335. CHINA POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 338. CHINA POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 339. CHINA POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 340. CHINA POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 341. CHINA POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 342. CHINA POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 343. CHINA POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 344. CHINA POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 345. CHINA POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 346. CHINA POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)